Iberdomide Combo Boosts Complete Response in Myeloma
A phase 3 trial showed that combining iberdomide with daratumumab and dexamethasone improved MRD-negative complete response rates in relapsed/refractory multiple myeloma patients compared to the standard regimen. The iberdomide group had a 41% response rate vs 21% in the control group, but higher adverse events. The study was published in The Lancet Oncology and supported by Bristol Myers Squibb, with some authors having ties to the company.
How this was made
The 30-second read
Why it matters
The data provide a clear efficacy signal that could accelerate regulatory approval and commercial launch, influencing BMY's valuation.
Market read
First‑report phase‑3 data for a late‑stage oncology drug, material for a large‑cap biotech, likely to move the stock.
What to watch
Potential competition from other CAR‑T or bispecific antibodies and the timeline for FDA filing are uncertain.
Background
The trial was funded by Celgene, a Bristol Myers Squibb subsidiary, and adds to the pipeline of cereblon E3 ligase modulators.
Ticker impact
Bristol Myers Squibb disclosed phase 3 trial results showing the iberdomide/daratumumab/dexamethasone regimen markedly improves MRD‑negative complete response rates in relapsed/refractory multiple myeloma.
likely upward pressure as the market prices in the efficacy advantage
Phase‑3 data are material for a large‑cap biotech; the magnitude of response improvement is sizable and may accelerate regulatory filing.
Market effects
Strengthens the multiple‑myeloma therapeutic segment and may boost peer biotech valuations.
U.S. biotech sector could see modest gains; European peers may be affected indirectly.
High relevance for global oncology investors tracking novel cereblon modulators.
Counterpoint
If safety concerns (high neutropenia and infection rates) outweigh efficacy, the stock could face pressure.
Key entities
- CompanyBristol Myers Squibb
Pharmaceutical company conducting the trial.
- SubsidiaryCelgene
Funding arm of the study.
